Suggested remit: To appraise the clinical and cost effectiveness of omburtamab I-131 within its marketing authorisation for treating relapsed neuroblastoma with central nervous system or leptomeningeal metastasis in children and young people.
Status In progress
Process STA 2018
ID number 1664

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
06 September 2021 (10:00) Scoping workshop
12 July 2021 - 09 August 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 August 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of omburtamab for treating relapsed neuroblastoma ID1664. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that is developing omburtamab, NICE has agreed that holding the scoping exercise at this time would not be appropriate. Consequently, NICE will not be progressing with the scoping exercise at this time, and the workshop arranged for Friday 28 August 2020 has been cancelled. Please accept our apologies for any inconvenience. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on
21 January 2020 In progress. Topic is proposed

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance